Skip Navigation

JNCI Journal of the National Cancer Institute 2006 98(6):372-373; doi:10.1093/jnci/djj115
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Woloshin, S.
Right arrow Articles by Schwartz, L. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Woloshin, S.
Right arrow Articles by Schwartz, L. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press.

EDITORIAL

What's the Rush? The Dissemination and Adoption of Preliminary Research Results

Steven Woloshin, Lisa M. Schwartz

Affiliations of authors: VA Outcomes Group, White River Junction, VT, and Center for the Evaluative Clinical Sciences, Dartmouth Medical School, Hanover, NH

Correspondence to: Lisa M. Schwartz, MD, MS, Department of Veterans Affairs Medical Center, VA Outcomes Group, Mail Stop 111B, 215 N. Main St., White River Junction, VT 05009 (lisa.m.schwartz@dartmouth.edu).

The first 10% of the full text of this article appears below.

How fast should the preliminary results of medical research be disseminated and adopted into clinical practice? In this issue of the Journal, Giordano et al. (1) provide an example of moving fast. They describe the substantial increase in use of taxane chemotherapy for women with node-positive breast cancer in the year following the presentation of the Cancer and Leukemia Group B (CALGB) 9344 study at the 1998 American Society of Clinical Oncology (ASCO) meeting—nearly 5 years before publication of the results in a peer-reviewed journal.

Moving fast is appealing. It means being on the cutting edge of medicine. It means bringing new hope to patients. There is a presumption that newer treatments are better than older ones. And all sorts of forces encourage the rapid adoption of new, so-called breakthrough treatments and technologies, including investigators with professional and financial interests, . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?